Phosphorylation of the C-Raf N Region Promotes Raf Dimerization

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular and Cellular Biology

• Publication date

  2017-07-10

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/MCB.00132-17PMID 28694330PMCID PMC5599720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dasatinib

  2019cited by this paper
• Inhibition of RAS function through targeting an allosteric regulatory site.

  2017cited by this paper
• Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

  2016cited by this paper
• Protein Kinase A-independent Ras Protein Activation Cooperates with Rap1 Protein to Mediate Activation of the Extracellular Signal-regulated Kinases (ERK) by cAMP*

  2016cited by this paper
• BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.

  2015cited by this paper
• Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation

  2015cited by this paper
• KRAS as a Therapeutic Target

  2015cited by this paper
• Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status

  2015cited by this paper
• Regulation of RAF protein kinases in ERK signalling

  2015cited by this paper
• Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway

  2015cited by this paper
• KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

  2014cited by this paper
• Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation

  2014cited by this paper
• Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells

  2014cited by this paper
• H-Ras forms dimers on membrane surfaces via a protein–protein interface

  2014cited by this paper
• Dragging ras back in the ring.

  2014cited by this paper
• Molecular mechanisms of asymmetric RAF dimer activation.

  2014cited by this paper
• Dimerization-induced allostery in protein kinase regulation.

  2014cited by this paper
• RAS's cloak of invincibility slips at last?

  2014cited by this paper
• Kinases and Pseudokinases: Lessons from RAF

  2014cited by this paper
• KRAS: feeding pancreatic cancer proliferation.

  2014cited by this paper
• Targeting RAS–ERK signalling in cancer: promises and challenges

  2014cited by this paper
• Allosteric activation of functionally asymmetric RAF kinase dimers.

  2013cited by this paper
• Protein Kinase A-dependent Phosphorylation of Rap1 Regulates Its Membrane Localization and Cell Migration*

  2013cited by this paper
• Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization

  2013cited by this paper
• Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling

  2013cited by this paper
• Ras-mutant Cancer Cells Display B-Raf Binding to Ras That Activates Extracellular Signal-regulated Kinase and Is Inhibited by Protein Kinase A Phosphorylation*

  2013cited by this paper
• Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling.

  2013influential reference
• Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins

  2013cited by this paper
• K-Ras4B lipoprotein synthesis: biochemical characterization, functional properties, and dimer formation.

  2012cited by this paper
• N-Ras forms dimers at POPC membranes.

  2012cited by this paper
• Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling

  2012cited by this paper
• Cancer therapy based on oncogene addiction

  2011cited by this paper
• RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

  2011cited by this paper
• Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors

  2011cited by this paper
• Mutant BRAF melanomas--dependence and resistance.

  2011cited by this paper
• Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase*

  2011cited by this paper
• Inhibition of Ras for cancer treatment: the search continues.

  2011cited by this paper
• Oncogenic Ras/Src cooperativity in pancreatic neoplasia

  2011cited by this paper
• Ras in cancer and developmental diseases.

  2011cited by this paper
• Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis

  2010cited by this paper
• Phenotype and Genotype of Pancreatic Cancer Cell Lines

  2010cited by this paper
• The Interaction of Epac1 and Ran Promotes Rap1 Activation at the Nuclear Envelope

  2010cited by this paper
• Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.

  2010cited by this paper
• A dimerization-dependent mechanism drives RAF catalytic activation

  2009cited by this paper
• Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

  2009cited by this paper
• A quantitative analysis of kinase inhibitor selectivity

  2008cited by this paper
• Raf kinases: function, regulation and role in human cancer.

  2007cited by this paper
• CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase activation.

  2007cited by this paper
• Oncogene addiction: setting the stage for molecularly targeted cancer therapy.

  2007cited by this paper
• Rap1-Mediated Activation of Extracellular Signal-Regulated Kinases by Cyclic AMP Is Dependent on the Mode of Rap1 Activation

  2006cited by this paper
• Regulation and Role of Raf-1/B-Raf Heterodimerization

  2006influential reference
• Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

  2006cited by this paper
• The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions

  2006cited by this paper
• Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.

  2005influential reference
• Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.

  2005cited by this paper
• B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms*

  2005cited by this paper
• c-Src and cooperating partners in human cancer.

  2004cited by this paper
• Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

  2004cited by this paper
• Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells

  2004cited by this paper
• The RAF proteins take centre stage

  2004cited by this paper
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004cited by this paper
• The Requirement of Specific Membrane Domains for Raf-1 Phosphorylation and Activation*

  2003cited by this paper
• Targeting RAS signalling pathways in cancer therapy

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Inducible gene deletion reveals different roles for B‐Raf and Raf‐1 in B‐cell antigen receptor signalling

  2002cited by this paper
• Active Ras induces heterodimerization of cRaf and BRaf.

  2001cited by this paper
• Phosphorylation site specificity of the Pak‐mediated regulation of Raf‐1 and cooperativity with Src

  2001cited by this paper
• Activation of B‐Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601

  2000cited by this paper
• Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation

  1999influential reference
• Oncogenes, growth factors and phorbol esters regulate Raf-1 through common mechanisms

  1998cited by this paper
• Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma.

  1998cited by this paper
• Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling

  1997cited by this paper
• Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases*

  1997cited by this paper
• Activation of c‐Raf‐1 by Ras and Src through different mechanisms: activation in vivo and in vitro

  1997cited by this paper
• Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

  1996cited by this paper
• Ras recruits Raf‐1 to the plasma membrane for activation by tyrosine phosphorylation.

  1995cited by this paper
• Activation of Raf as a result of recruitment to the plasma membrane.

  1994cited by this paper
• Raf-1 interacts with Fyn and Src in a non-phosphotyrosine-dependent manner.

  1994cited by this paper
• A single amino acid change in Raf-1 inhibits Ras binding and alters Raf-1 function.

  1994cited by this paper
• Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase

  1993cited by this paper
• Identification of the major phosphorylation sites of the Raf-1 kinase.

  1993cited by this paper
• Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase.

  1992cited by this paper
• The Raf-1 serine-threonine kinase is a substrate for the p56lck protein tyrosine kinase in human T-cells.

  1991cited by this paper

• In-cell single-molecule FRET measurement of cytosolic RAF proteins to investigate the structural states and kinetics among them

  2025cites this paper
• Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation

  2025influential citation
• Lithium suppresses the Ras-Raf-MEK-ERK signaling in CD4 T cells and impairs the humoral immune system.

  2025cites this paper
• RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor

  2025cites this paper
• Cryo-EM structures of CRAF2/14-3-32 and CRAF2/14-3-32/MEK12 complexes.

  2024cites this paper
• Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma

  2024cites this paper
• SIRT4 as a novel interactor and candidate suppressor of C-RAF kinase in MAPK signaling

  2024cites this paper
• Discovery of New Quinolone-Based Diarylamides as Potent B-RAFV600E/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity

  2023cites this paper
• Identification of SIRT4 as a novel paralog-specific interactor and candidate suppressor of C-RAF kinase in MAPK signaling

  2023cites this paper
• Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib

  2023cites this paper
• A novel phosphorylation site involved in dissociating RAF kinase from the scaffolding protein 14-3-3 and disrupting RAF dimerization

  2023cites this paper
• The Agonist of Adenosine A1 Receptor Induced Desensitization of delta Opioid receptor-mediated Raf-1/MEK/ERK Signaling by Feedback Phosphorylation of Raf-1-Ser289/296/301

  2022cites this paper
• Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway

  2022cites this paper
• Multiplexed Digital Spatial Protein Profiling Reveals a Unique Protein Signature for Advanced Liver Fibrosis

  2022cites this paper
• Multiplexed Digital Spatial Protein Profiling Reveals Distinct Phenotypes of Mononuclear Phagocytes in Livers with Advanced Fibrosis

  2022cites this paper
• The sodium channel subunit SCNN1B suppresses colorectal cancer via suppression of active c-Raf and MAPK signaling cascade

  2022cites this paper
• β2-Adrenoceptor Agonists Promote Extracellular Signal-Regulated Kinase 1/2 Dephosphorylation in Human Airway Epithelial Cells by Canonical, cAMP-Driven Signaling Independently of β-Arrestin 2

  2021cites this paper
• High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma

  2021cites this paper
• b 2 -Adrenoceptor Agonists Promote Extracellular Signal-Regulated Kinase 1/2 Dephosphorylation in Human Airway Epithelial Cells by Canonical, cAMP-Driven Signaling Independently of b -Arrestin 2 S

  2021cites this paper
• RAF kinase dimerization: implications for drug discovery and clinical outcomes

  2020cites this paper
• Miquelianin Inhibits Allergic Responses in Mice by Suppressing CD4+ T Cell Proliferation

  2020cites this paper
• Inhibition of RAF dimers: it takes two to tango

  2020cites this paper
• Optical control of ERK and AKT signaling promotes axon regeneration and functional recovery of PNS and CNS in Drosophila

  2020cites this paper
• Three distinct regions of cRaf kinase domain interact with membrane

  2019cites this paper
• SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions

  2019cites this paper
• SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics

  2019cites this paper
• RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling

  2018cites this paper